S&P 500   3,962.10 (+1.56%)
DOW   31,855.27 (+1.90%)
QQQ   292.98 (+1.49%)
AAPL   142.79 (+3.78%)
MSFT   260.86 (+3.29%)
FB   195.89 (+1.21%)
GOOGL   2,234.40 (+2.58%)
AMZN   2,123.26 (-1.33%)
TSLA   674.71 (+1.63%)
NVDA   167.37 (+0.26%)
BABA   87.20 (+0.47%)
NIO   15.82 (-3.77%)
AMD   94.00 (+0.53%)
CGC   5.29 (-4.17%)
MU   69.61 (+1.03%)
T   20.81 (+2.01%)
GE   75.98 (+0.97%)
F   12.89 (+3.12%)
DIS   104.90 (+2.42%)
AMC   11.70 (-2.74%)
PFE   53.21 (+1.41%)
PYPL   81.59 (+1.30%)
NFLX   185.25 (-0.59%)
S&P 500   3,962.10 (+1.56%)
DOW   31,855.27 (+1.90%)
QQQ   292.98 (+1.49%)
AAPL   142.79 (+3.78%)
MSFT   260.86 (+3.29%)
FB   195.89 (+1.21%)
GOOGL   2,234.40 (+2.58%)
AMZN   2,123.26 (-1.33%)
TSLA   674.71 (+1.63%)
NVDA   167.37 (+0.26%)
BABA   87.20 (+0.47%)
NIO   15.82 (-3.77%)
AMD   94.00 (+0.53%)
CGC   5.29 (-4.17%)
MU   69.61 (+1.03%)
T   20.81 (+2.01%)
GE   75.98 (+0.97%)
F   12.89 (+3.12%)
DIS   104.90 (+2.42%)
AMC   11.70 (-2.74%)
PFE   53.21 (+1.41%)
PYPL   81.59 (+1.30%)
NFLX   185.25 (-0.59%)
S&P 500   3,962.10 (+1.56%)
DOW   31,855.27 (+1.90%)
QQQ   292.98 (+1.49%)
AAPL   142.79 (+3.78%)
MSFT   260.86 (+3.29%)
FB   195.89 (+1.21%)
GOOGL   2,234.40 (+2.58%)
AMZN   2,123.26 (-1.33%)
TSLA   674.71 (+1.63%)
NVDA   167.37 (+0.26%)
BABA   87.20 (+0.47%)
NIO   15.82 (-3.77%)
AMD   94.00 (+0.53%)
CGC   5.29 (-4.17%)
MU   69.61 (+1.03%)
T   20.81 (+2.01%)
GE   75.98 (+0.97%)
F   12.89 (+3.12%)
DIS   104.90 (+2.42%)
AMC   11.70 (-2.74%)
PFE   53.21 (+1.41%)
PYPL   81.59 (+1.30%)
NFLX   185.25 (-0.59%)
S&P 500   3,962.10 (+1.56%)
DOW   31,855.27 (+1.90%)
QQQ   292.98 (+1.49%)
AAPL   142.79 (+3.78%)
MSFT   260.86 (+3.29%)
FB   195.89 (+1.21%)
GOOGL   2,234.40 (+2.58%)
AMZN   2,123.26 (-1.33%)
TSLA   674.71 (+1.63%)
NVDA   167.37 (+0.26%)
BABA   87.20 (+0.47%)
NIO   15.82 (-3.77%)
AMD   94.00 (+0.53%)
CGC   5.29 (-4.17%)
MU   69.61 (+1.03%)
T   20.81 (+2.01%)
GE   75.98 (+0.97%)
F   12.89 (+3.12%)
DIS   104.90 (+2.42%)
AMC   11.70 (-2.74%)
PFE   53.21 (+1.41%)
PYPL   81.59 (+1.30%)
NFLX   185.25 (-0.59%)
NASDAQ:CTMX

CytomX Therapeutics (CTMX) Stock Forecast, Price & News

$1.57
-0.05 (-3.09%)
(As of 05/23/2022 12:33 PM ET)
Add
Compare
Today's Range
$1.53
$1.64
50-Day Range
$1.53
$3.47
52-Week Range
$1.51
$8.63
Volume
24,817 shs
Average Volume
953,417 shs
Market Capitalization
$102.67 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.76
30 days | 90 days | 365 days | Advanced Chart
Receive CTMX News and Ratings via Email

Sign-up to receive the latest news and ratings for CytomX Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

CytomX Therapeutics logo

About CytomX Therapeutics

CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical trials for the treatment of breast cancer; CX-2029 that is in Phase II clinical trials for the treatment of squamous non-small cell lung cancer, head and neck squamous cell carcinoma, esophageal and gastro-esophageal junction cancers, and diffuse large B-cell lymphoma; BMS-986249, a CTLA-4 Probody therapeutic drug, which is in Phase I/II clinical trials for the treatment of metastatic melanoma; and BMS-986288, an anti-CTLA-4 Probody drug, which is in Phase I clinical trials for the treatment of solid tumors. It also develops CX-2043, a conditionally activated ADC targeting the epithelial cell adhesion molecule, as well as CX-904, a conditionally activated epidermal growth factor receptor for the treatment of solid tumor. The company has strategic collaborations with AbbVie Ireland Unlimited Company, Amgen, Inc., Bristol-Myers Squibb Company, ImmunoGen, Inc., Pfizer Inc., and Astellas Pharma Inc. to develop Probody therapeutics. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CTMX
Employees
174
Year Founded
N/A

Sales & Book Value

Annual Sales
$69.57 million
Book Value
$1.04 per share

Profitability

Net Income
$-83.61 million
Net Margins
-129.97%
Pretax Margin
-129.97%

Debt

Price-To-Earnings

Miscellaneous

Free Float
62,390,000
Market Cap
$102.67 million
Optionable
Optionable

Company Calendar

Last Earnings
5/05/2022
Today
5/23/2022
Next Earnings (Estimated)
8/04/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

1.97 out of 5 stars

Medical Sector

633rd out of 1,416 stocks

Pharmaceutical Preparations Industry

290th out of 677 stocks

Analyst Opinion: 3.5Community Rank: 4.7Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -













CytomX Therapeutics (NASDAQ:CTMX) Frequently Asked Questions

Is CytomX Therapeutics a buy right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for CytomX Therapeutics in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CytomX Therapeutics stock.
View analyst ratings for CytomX Therapeutics
or view top-rated stocks.

Are investors shorting CytomX Therapeutics?

CytomX Therapeutics saw a increase in short interest during the month of April. As of April 30th, there was short interest totaling 3,800,000 shares, an increase of 37.7% from the April 15th total of 2,760,000 shares. Based on an average daily trading volume, of 971,800 shares, the days-to-cover ratio is currently 3.9 days. Approximately 6.2% of the company's stock are sold short.
View CytomX Therapeutics' Short Interest
.

When is CytomX Therapeutics' next earnings date?

CytomX Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for CytomX Therapeutics
.

How were CytomX Therapeutics' earnings last quarter?

CytomX Therapeutics, Inc. (NASDAQ:CTMX) released its earnings results on Thursday, May, 5th. The biotechnology company reported ($0.37) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.35) by $0.02. CytomX Therapeutics had a negative trailing twelve-month return on equity of 91.89% and a negative net margin of 129.97%. During the same period in the previous year, the firm earned ($0.26) earnings per share.
View CytomX Therapeutics' earnings history
.

What price target have analysts set for CTMX?

6 Wall Street analysts have issued 12-month price targets for CytomX Therapeutics' stock. Their forecasts range from $6.00 to $16.00. On average, they anticipate CytomX Therapeutics' stock price to reach $10.83 in the next twelve months. This suggests a possible upside of 590.0% from the stock's current price.
View analysts' price targets for CytomX Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are CytomX Therapeutics' key executives?
CytomX Therapeutics' management team includes the following people:
  • Dr. Sean A. McCarthy D.Phil., DPHIL, Chairman & CEO (Age 55, Pay $980.33k)
  • Dr. Amy C. Peterson M.D., Pres & COO (Age 55, Pay $792.41k)
  • Mr. Frederick W. Gluck, Co-Founder & Independent Director (Age 87, Pay $40k)
  • Mr. Carlos Campoy, Sr. VP & CFO (Leave of Absence) (Age 56, Pay $678.35k)
  • Mr. Lloyd A. Rowland Jr., J.D., Sr. VP, Gen. Counsel, Chief Compliance Officer & Sec. (Age 65, Pay $594.07k)
  • Dr. Alison L. Hannah M.D., Sr. VP & Chief Medical Officer (Age 61, Pay $659.8k)
  • Mr. Christopher W. Ogden, Interim Principal Accounting Officer and VP of Fin. & Accounting (Age 38)
  • Dr. Chau Cheng M.B.A., Ph.D., VP of Investor Relations & Corp. Communications
  • Ms. Danielle Olander, Sr. VP, Talent & Systems Devel.
  • Ms. Leslie Robbins, Sr. VP of Intellectual Property
What is Sean A McCarthy's approval rating as CytomX Therapeutics' CEO?

11 employees have rated CytomX Therapeutics CEO Sean A McCarthy on Glassdoor.com. Sean A McCarthy has an approval rating of 65% among CytomX Therapeutics' employees.

What other stocks do shareholders of CytomX Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other CytomX Therapeutics investors own include Gilead Sciences (GILD), Exelixis (EXEL), AbbVie (ABBV), Inovio Pharmaceuticals (INO), Corbus Pharmaceuticals (CRBP), Pfizer (PFE), SCYNEXIS (SCYX), Bausch Health Companies (BHC), Bristol-Myers Squibb (BMY) and Dynavax Technologies (DVAX).

What is CytomX Therapeutics' stock symbol?

CytomX Therapeutics trades on the NASDAQ under the ticker symbol "CTMX."

Who are CytomX Therapeutics' major shareholders?

CytomX Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include RTW Investments LP (8.84%), Vanguard Group Inc. (7.99%), BlackRock Inc. (7.63%), Candriam Luxembourg S.C.A. (2.53%), Healthcare of Ontario Pension Plan Trust Fund (1.97%) and State Street Corp (1.83%).
View institutional ownership trends for CytomX Therapeutics
.

Which institutional investors are selling CytomX Therapeutics stock?

CTMX stock was sold by a variety of institutional investors in the last quarter, including State Street Corp, RTW Investments LP, Candriam Luxembourg S.C.A., Russell Investments Group Ltd., Northern Trust Corp, Engineers Gate Manager LP, California State Teachers Retirement System, and MetLife Investment Management LLC.
View insider buying and selling activity for CytomX Therapeutics
or view top insider-selling stocks.

Which institutional investors are buying CytomX Therapeutics stock?

CTMX stock was purchased by a variety of institutional investors in the last quarter, including Healthcare of Ontario Pension Plan Trust Fund, Acadian Asset Management LLC, Renaissance Technologies LLC, Dimensional Fund Advisors LP, Goldman Sachs Group Inc., Vanguard Group Inc., XTX Topco Ltd, and CI Investments Inc..
View insider buying and selling activity for CytomX Therapeutics
or or view top insider-buying stocks.

How do I buy shares of CytomX Therapeutics?

Shares of CTMX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is CytomX Therapeutics' stock price today?

One share of CTMX stock can currently be purchased for approximately $1.57.

How much money does CytomX Therapeutics make?

CytomX Therapeutics has a market capitalization of $102.67 million and generates $69.57 million in revenue each year. The biotechnology company earns $-83.61 million in net income (profit) each year or ($1.420010) on an earnings per share basis.

How many employees does CytomX Therapeutics have?

CytomX Therapeutics employs 174 workers across the globe.

What is CytomX Therapeutics' official website?

The official website for CytomX Therapeutics is www.cytomx.com.

How can I contact CytomX Therapeutics?

CytomX Therapeutics' mailing address is 151 OYSTER POINT BLVD.SUITE 400, SOUTH SAN FRANCISCO CA, 94080. The biotechnology company can be reached via phone at (605) 515-3185, via email at [email protected], or via fax at 650-351-0353.

This page was last updated on 5/23/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.